YDYannick Debing

Yannick Debing

*This is an algorithmically generated author record based on publicly available information.

Yannick Debing has a total of 138 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Antiviral profile of hepatitis B virus capsid assembly modulator ALG-001075, the parent of pevifoscorvir sodium

    by Yannick Debing, Hannah Vanrusselt, Cheng Liu, Jordi Verheyen, Lars Degrauwe, Dieudonné Buh Kum, Abel Acosta Sanchez, Adilson Carlos Francisco, Emma Wanicek, Hans J. Netter, et al.

  • The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075

    by Sandrine Vendeville, Franck Amblard, Leda Bassit, Leonid N. Beigelman, Lawrence M. Blatt, Xiaoyuan Chen, Lang Chou, Dieudonné Buh Kum, Sushmita Chanda, Jerome Deval, et al.

    Chronic hepatitis B (CHB) represents a significant unmet medical need with few options beyond lifelong treatment with nucleoside analogues, which rarely leads to a functional cure. Novel agents that reduce levels of HBV DNA, RNA and other viral antigens could lead to better treatment outcomes. The capsid assembly modulator (CAM) class of compounds represents an important modality for chronic suppression and to improve functional cure rates, either alone or in combination. GLP-26 is a potent CAM, which in this work was optimized for potency, safety, and other drug-like properties leading to ALG-001075. ALG-001075 was further advanced through clinical development as the highly soluble prodrug ALG-000184. ALG-000184 is currently being explored in multiple clinical trials in HBV-infected subjects where unprecedented reductions in HBV DNA, RNA and other viral antigens have been observed, making ALG-000184 a promising candidate to become a cornerstone for future chronic suppressive and combination treatment regimens for CHB.


  • Open Access

    CAM-A-dependent HBV core aggregation induces apoptosis through ANXA1

    by Valerio Taverniti, Laura Meiss-Heydmann, Cloé Gadenne, Hannah Vanrusselt, Dieudonné Buh Kum, Fabio Giannone, Patrick Pessaux, Catherine Schuster, Thomas F. Baumert, Yannick Debing, et al.


  • An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients

    by Yannick Debing, Hannah Vanrusselt, Lars Degrauwe, Daniel Apolônio Silva de Oliveira, Christopher Kinyanjui Kariuki, Ebanja Joseph Ebwanga, Shahbaz Bashir, Wouter Merckx, Santhosh Kumar Thatikonda, Vivek Rajwanshi, et al.

  • Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles

    by Hannah Vanrusselt, Dieudonné Buh Kum, Valerio Taverniti, Cheng Liu, Abel Acosta Sanchez, Nikky Corthout, Sebastian Munck, Thomas F. Baumert, Leonid Beigelman, Lawrence M. Blatt, et al.

    Capsid assembly modulators (CAMs) are a novel class of therapeutic small molecules with the potential to address the continued global challenge posed by chronic hepatitis B (CHB). Class A CAMs (CAM-As) are particularly attractive because they induce loss of hepatitis B virus (HBV)-infected hepatocytes in animal models. All CAM-As described to date are heteroaryldihydropyrimidines (HAPs) which come with several drawbacks. Here, we report on the first non-HAP CAM-As ALG-005398 and ALG-005863 and provide a detailed in vitro intracellular characterization. These non-HAP CAM-As are potent inhibitors of HBV DNA production and also block the establishment of cccDNA. Non-HAP CAM-As can be classified into two distinct profiles: CAM-A i and CAM-A t , which are in turn differentiated from the HAP CAM-A h profile. CAM-A i molecules induce larger and more irregular capsids in electron microscopy and cellular HBV core protein (HBc) staining, whereas CAM-A t -induced capsids and aggregates are smaller but more numerous. CAM-A i and CAM-A t also induce a different subnuclear localization (no co-localization with promyelocytic leukemia bodies) and show a lower propensity to CAM-A-induced HBc-dependent cell death compared to CAM-A h . CAM-A t s ALG-005398 and ALG-006162 showed steady reductions of circulating HBsAg and HBeAg with minimal alanine aminotransferase (ALT) elevation in the adeno-associated virus (AAV)-HBV mouse model, accompanied by loss of the AAV-HBV episome and infected hepatocytes. Moreover, these effects were sustained for at least 13 weeks after end of treatment. The differentiated mechanism of action and sustained in vivo response make non-HAP CAM-As a promising potential component of future functional cure regimens for CHB patients. IMPORTANCE: Chronic hepatitis B is the most important cause of liver cancer worldwide and affects more than 290 million people. Current treatments are mostly suppressive and rarely lead to a cure. Therefore, there is a need for novel and curative drugs that target the host or the causative agent, hepatitis B virus itself. Capsid assembly modulators are an interesting class of antiviral molecules that may one day become part of curative treatment regimens for chronic hepatitis B. Here we explore the characteristics of a particularly interesting subclass of capsid assembly modulators. These so-called non-HAP CAM-As have intriguing properties in cell culture but also clear virus-infected cells from the mouse liver in a gradual and sustained way. We believe they represent a considerable improvement over previously reported molecules and may one day be part of curative treatment combinations for chronic hepatitis B.


  • Open Access

    Establishment of a robust rat hepatitis E virus fecal-oral infection model and validation for antiviral studies

    by Xin Zhang, Niels Cremers, Stijn Hendrickx, Yannick Debing, Tania Roskams, Lotte Coelmont, Johan Neyts, Suzanne J.F. Kaptein


  • Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation

    by Dieudonné Buh Kum, Hannah Vanrusselt, Abel Acosta Sanchez, Valerio Taverniti, Eloi R. Verrier, Thomas F. Baumert, Cheng Liu, Jerome Deval, Nikky Corthout, Sebastian Munck, et al.

    Background and Aims: Effective therapies leading to a functional cure for chronic hepatitis B are still lacking. Class A capsid assembly modulators (CAM-As) are an attractive modality to address this unmet medical need. CAM-As induce aggregation of the HBV core protein (HBc) and lead to sustained HBsAg reductions in a chronic hepatitis B mouse model. Here, we investigate the underlying mechanism of action for CAM-A compound RG7907. Approach and Results: RG7907 induced extensive HBc aggregation in vitro, in hepatoma cells, and in primary hepatocytes. In the adeno-associated virus (AAV)–HBV mouse model, the RG7907 treatment led to a pronounced reduction in serum HBsAg and HBeAg, concomitant with clearance of HBsAg, HBc, and AAV-HBV episome from the liver. Transient increases in alanine transaminase, hepatocyte apoptosis, and proliferation markers were observed. These processes were confirmed by RNA sequencing, which also uncovered a role for interferon alpha and gamma signaling, including the interferon-stimulated gene 15 (ISG15) pathway. Finally, the in vitro observation of CAM-A–induced HBc–dependent cell death through apoptosis established the link of HBc aggregation to in vivo loss of infected hepatocytes. Conclusions: Our study unravels a previously unknown mechanism of action for CAM-As such as RG7907 in which HBc aggregation induces cell death, resulting in hepatocyte proliferation and loss of covalently closed circular DNA or its equivalent, possibly assisted by an induced innate immune response. This represents a promising approach to attain a functional cure for chronic hepatitis B.


  • Open Access

    Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives

    by Valerio Taverniti, Gaëtan Ligat, Yannick Debing, Dieudonne Buh Kum, Thomas F. Baumert, Eloi R. Verrier

    Despite a preventive vaccine being available, more than 250 million people suffer from chronic hepatitis B virus (HBV) infection, a major cause of liver disease and HCC. HBV infects human hepatocytes where it establishes its genome, the cccDNA with chromosomal features. Therapies controlling HBV replication exist; however, they are not sufficient to eradicate HBV cccDNA, the main cause for HBV persistence in patients. Core protein is the building block of HBV nucleocapsid. This viral protein modulates almost every step of the HBV life cycle; hence, it represents an attractive target for the development of new antiviral therapies. Capsid assembly modulators (CAM) bind to core dimers and perturb the proper nucleocapsid assembly. The potent antiviral activity of CAM has been demonstrated in cell-based and in vivo models. Moreover, several CAMs have entered clinical development. The aim of this review is to summarize the mechanism of action (MoA) and the advancements in the clinical development of CAMs and in the characterization of their mod of action.


  • Open Access

    Genome Sequences and Phylogeny of Two Duck Hepatitis B Viruses

    by Daniel Apolônio Silva de Oliveira, Yannick Debing, Ines Dieryck, Wilfred Michael Lyimu, Jan Paeshuyse

    Duck hepatitis B virus (DHBV) infection in Pekin ducks is a model for human hepatitis B. Sequence variations may contribute to host therapy responses against the virus. We provide full genome sequences of two DHBVs from France, their phylogenetic classification, and their sequence variability.


  • Open Access

    Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication

    by Wenshi Wang, Yijin Wang, Yannick Debing, Xinying Zhou, Yuebang Yin, Lei Xu, Elena Herrera Carrillo, Johannes H. Brandsma, Raymond A. Poot, Ben Berkhout, et al.